News ASCO26: Celcuity punished as trial disappoints investors Celcuity is still confident it has a winner with its breast cancer treatment, gedatolisib, but investors seem less convinced by new VIKTORIA-1 data.
News Late-breakers to look out for at ASCO 2026 ASCO is just around the corner, and there is the usual fertile crop of high-profile trials to look out for among the late-breaker presentations.
News 11 high-impact drugs to look out for in 2026 Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year.
News Celcuity eyes big market opportunity after breast cancer win Celcuity shares rocket on a big win for its lead drug gedatolisib in advanced breast cancer, catapulting its value to almost $1.4 billion.
Oncology ASCO 2026: Can a blood test spot cancer early? with Dr Peter... Dr Peter Sasieni, co-investigator for the NHS Galleri trial, discusses advances in population-level blood screening for early cancer detection.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.